Copyright
©The Author(s) 2021.
World J Gastroenterol. Jul 28, 2021; 27(28): 4493-4503
Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4493
Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4493
Figure 1 Disease-free survival in the study population (CheckMate 577).
Citation: Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 2021; 384(13): 1191-1203. Copyright ©The Authors 2021. Published by Massachusetts Medical Society[7]. DFS: Disease-free survival.
- Citation: Bordry N, Astaras C, Ongaro M, Goossens N, Frossard JL, Koessler T. Recent advances in gastrointestinal cancers. World J Gastroenterol 2021; 27(28): 4493-4503
- URL: https://www.wjgnet.com/1007-9327/full/v27/i28/4493.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i28.4493